A Structure-Activity Relationship Study of Novel Positive Allosteric Modulators for the δ-Opioid Receptor.

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Chronic pain and depression frequently co-occur, necessitating safer and more effective treatments.
• Current μ-opioid receptor (MOR) agonists for pain relief have significant risks like addiction and respiratory depression.
• δ-opioid receptor (DOR) agonists present a safer alternative for pain management with a reduced side effect profile.

Purpose of the Study:

• To develop novel δ-opioid receptor (DOR) positive allosteric modulators (PAMs) with improved selectivity and reduced lipophilicity.
• To investigate the structure-activity relationship (SAR) of DOR PAMs for enhanced therapeutic potential.
• To design drug-like therapeutics targeting DOR with specific signaling pathway preferences.

Main Methods:

• Focused SAR studies on DOR PAMs to optimize selectivity and drug-like properties.
• Development of a novel tetrazoloquinazolinone scaffold.
• Assessment of signaling pathway bias, favoring G protein over β-arrestin2 recruitment.

Main Results:

• A novel tetrazoloquinazolinone scaffold was successfully developed.
• The new scaffold demonstrated favorable G protein-pathway signaling over β-arrestin2 recruitment.
• The developed compounds show potential for DOR-targeted therapeutics with specific signaling profiles.

Conclusions:

• The novel tetrazoloquinazolinone scaffold is a promising foundation for developing new δ-opioid receptor (DOR) therapeutics.
• These findings could lead to improved treatments for chronic pain and depression with reduced side effects.
• The scaffold provides a valuable platform for further structural and pharmacological studies.